公开(公告)号：US20100172931A1

公开(公告)日：2010-07-08

申请号：US12664278

申请日：2008-06-16

申请人： Rolando Pajon Feyt ,  Olivia Niebla Perez ,  Gretel Sardinas Garcia ,  Sonia Gonzalez Blanco ,  Darien Garcia Diaz ,  Evelin Caballero Menendez ,  Karem Cobas Acosta

发明人： Rolando Pajon Feyt ,  Olivia Niebla Perez ,  Gretel Sardinas Garcia ,  Sonia Gonzalez Blanco ,  Darien Garcia Diaz ,  Evelin Caballero Menendez ,  Karem Cobas Acosta

IPC分类号： A61K39/095 ,  C07K14/22 ,  A61K39/385 ,  C12Q1/02 ,  A61P31/04

CPC分类号： A61K39/095 ,  A61K2039/55583

摘要： The present invention is related to field of medicine, particularly to the development of pharmaceutical composition containing the NMB1796 protein. The composition described in this invention are able to confer protection against different diseases caused or not by pathogenic agents. The NMB1796 protein was identified as a Neisseria meningitidis outer membrane vesicle (OMV) component, and it was obtained through recombinant DNA technology being its immunogenicity and protective activity evaluated in animal models. Due to the high level of conservation that the NMB1796 coding gene has shown, pharmaceutical compositions containing this protein have a high value as inducers of a cross-reactive immune response. The composition presented in this invention is applicable to the field of human medicine.

摘要翻译： 本发明涉及药物领域，特别涉及含有NMB1796蛋白质的药物组合物的开发。 本发明中描述的组合物能够赋予针对由病原体引起或不由病原体引起的不同疾病的保护作用。 NMB1796蛋白被鉴定为脑膜炎奈瑟氏球菌外膜囊泡（OMV）组分，通过重组DNA技术获得其在动物模型中评估的免疫原性和保护活性。 由于NMB1796编码基因表现出高度的保守性，含有该蛋白质的药物组合物具有作为交叉反应性免疫应答诱导剂的高价值。 本发明提供的组合物可应用于人类医学领域。